BASEL, Switzerland and IRVINE, Calif., Feb. 28, 2018 /PRNewswire/ -- Urovant Sciences, aglobal biopharmaceutical company focused on developing novel therapies for urologic conditions, today announced that clinical data from a Phase 2b study of vibegron will be presented at two upcoming medical congresses.
Details for both presentations are as follows:
SUFU Oral Presentation
AUA Oral Presentation
About Overactive Bladder
Overactive bladder (OAB) is a condition that affects as many as 46 million adults in the United States alone. The most common symptoms of OAB include the experience of sudden urges to urinate that cannot be controlled, frequent urination, and urinary incontinence due to involuntary contractions of the detrusor muscle. While several conditions may contribute to signs and symptoms of overactive bladder, the underlying cause of OAB remains unclear.
Vibegron is an investigational oral ?3-adrenergic agonist being studied for the treatment of OAB. ?3-adrenergic receptors play a role in the bladder fill-void cycle. By stimulating that pathway, vibegron has the potential to relax the bladder detrusor muscle. Relaxing the bladder allows it to store urine more efficiently, thereby decreasing the symptoms of OAB. Over 2,700 patients with symptoms of OAB have previously been enrolled in clinical studies evaluating the safety and efficacy of vibegron.
About Urovant Sciences
Urovant Sciences is a global biopharmaceutical company focused on developing novel therapies for urologic conditions. Urovant's lead therapeutic candidate is vibegron, a potent and selective ?3-adrenergic agonist being developed for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.
Urovant has licensed global rights, excluding Japan and certain Asian territories, for the development and commercialization of vibegron. Urovant intends to develop treatments for additional urologic diseases. For more information, please visit urovant.com.
Contact: Paul DavisRoivant Sciences, Inc. email@example.com
View original content:http://www.prnewswire.com/news-releases/urovant-sciences-announces-upcoming-presentations-of-data-from-phase-2b-trial-of-vibegron-in-patients-with-overactive-bladder-300605585.html
SOURCE Urovant Sciences
Subscribe to our Free Newsletters!
Stiff joints are a major problem for the elderly, as the joints tend to wear-and-tear with ...
Uterine/Endometrial cancer is the sixth most common cancer in women worldwide. Uterine cancer ...View All